Sonoma Pharmaceuticals, Inc. (SNOA)
NASDAQ: SNOA · Real-Time Price · USD
4.830
-0.260 (-5.11%)
At close: Aug 25, 2025, 4:00 PM
4.800
-0.030 (-0.62%)
After-hours: Aug 25, 2025, 4:04 PM EDT
Sonoma Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Sonoma Pharmaceuticals.
Price Target: $ (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Sonoma Pharmaceuticals.
Recommendation Trends
| Rating | Jun '23 | Jul '23 | Aug '23 | Sep '23 |
|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +1,245.76% | Sep 5, 2023 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 6, 2018 |
| Maxim Group | Maxim Group | Strong Buy Maintains $1,800 → $1,980 | Strong Buy | Maintains | $1,800 → $1,980 | +40,893.79% | Nov 10, 2017 |
Financial Forecast
Revenue This Year
17.57M
from 14.29M
Increased by 23.00%
Revenue Next Year
21.90M
from 17.57M
Increased by 24.59%
EPS This Year
-1.34
from -2.79
EPS Next Year
-0.46
from -1.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 18.1M | 22.5M |
| Avg | 17.6M | 21.9M |
| Low | 16.9M | 21.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 26.6% | 28.3% |
| Avg | 23.0% | 24.6% |
| Low | 18.2% | 19.7% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -1.38 | -0.48 |
| Avg | -1.34 | -0.46 |
| Low | -1.29 | -0.44 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.